Clinical Research and Experimental Study on Xihuang Pill Treating Breast Cancer based on Estrogen Receptor

PAN Guo-feng

您当前的位置：

首页 >

文章列表页 >

Clinical Research and Experimental Study on Xihuang Pill Treating Breast Cancer based on Estrogen Receptor

更新时间：2024-01-04

- Clinical Research and Experimental Study on Xihuang Pill Treating Breast Cancer based on Estrogen Receptor
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 18, Issue 23, Pages: 330-333(2012)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published：2012
- 稿件说明：
移动端阅览
PAN Guo-feng. Clinical Research and Experimental Study on Xihuang Pill Treating Breast Cancer based on Estrogen Receptor[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(23): 330-333.
DOI：

PAN Guo-feng. Clinical Research and Experimental Study on Xihuang Pill Treating Breast Cancer based on Estrogen Receptor[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(23): 330-333. DOI：

摘要

目的: 探讨西黄丸对雌激素受体不同状态乳腺癌的选择性作用。方法: 雌激素依赖性与非雌激素依赖性乳腺癌患者各30例

数字随机法分别分为治疗组与对照组各15例

雌激素依赖性乳腺癌患者口服来曲唑2.5 mg/次

1次/d

30 d为1个疗程

治疗组A在内分泌治疗的基础上加用西黄丸3 g/瓶

3 g/次

2次/d;非雌激素依赖性乳腺癌患者治疗组B服用西黄丸

对照组B不做处理

观察中医证候与生活质量变化及肿瘤标志物(CA50

CEA CA153)等。MTT法检测西黄丸含药血清对人乳腺癌细胞株MCF-7与MDA-MB-231的抑制率。结果: 雌激素依赖性乳腺癌治疗组A与对照组A生活质量改善率分别为60%

40%(P<0.05)

临床症候总改善率分别为73.3%

53.3%(P<0.05);非雌激素依赖性乳腺癌治疗组B与对照组B生活质量改善率分别为46.7%、33.3%(P<0.05)

临床症候总改善率分别为66.7%

46.7%(P<0.05);雌激素依赖性乳腺癌治疗组A与对照组A CA153下降值比较差异有统计学意义(P<0.05)

CA50

CEA变化与对照组无显著差异;非雌激素依赖性乳腺癌治疗组B与对照组B相比

各肿瘤标志物变化均无显著差异。西黄丸含药血清对人乳腺癌细胞MCF-7(ER+)在含药血清浓度6.25%~25%有一定抑制作用

对MDA-MB-231(ER-)细胞株基本无抑制作用

相反有不同程度的促进作用。结论: 西黄丸联合内分泌治疗雌激素依赖性乳腺癌具有一定减毒增效作用

且其疗效优于非雌激素依赖性乳腺癌的临床疗效;西黄丸对(ER)不同状态乳腺癌具有一定选择性作用。

Abstract

Objective: To investigate the selective effect of Xihuang Pill on-estrogen receptor status of breast cancer. Method: Thirty estrogen-dependent breast cancer patients and 30 non-estrogen-dependent breast cancer patients were respectively randomLy assigned to two groups by digital table. The estrogen-dependent breast cancer patients used Letrozole 2.5 mg·qd. for 30 d and the treatment one was added with Xihuang Pill 3 g

bid for 30 d. The treatment group of non estrogen-dependent breast cancer patients were treated with Xihuang Pill. All the patients were observed their Traditional Chinese Medicine (TCM) syndrome

quality of life and tumor mark of breast cancer (CA50

CEA

CA153s)as well. MTT assay was used to assessed the viability of human breast cancer cell lines MCF-7 and MDA-MB-231 submitted to Xihuang Pill drug serum. Result: The treatment group and control group of estrogen-dependent breast cancer patients in improvement of quality of life was respectively 60%

40% (P<0.05)

and the total improvement rate of TCM syndrome was respectively 73.3%

53.3% (P<0.05). While the non estrogen-dependent one quality of life was respectively 46.7%

33.3%(P<0.05)

and the total improvement rate of TCM syndrome wais respectively 66.7%

46.7% (P<0.05). The CA153 values of treatment group and the control group of estrogen-dependent breast patients had a significant difference (P<0.05). Xihuang pill drug serum slightly decreased MCF-7 proliferation in the serum concentrations of 6.25%-25% in vivo

but promote proliferation of MDA-MB-231 instead. Conclusion: Xihuang pill had attenuated synergistic effect on estrogen-dependent breast cancer combined with Letrozole. And the curative effect was better than that of non-estrogen-dependent breast cancer

which showed its selective effect.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploring Mechanism of Breast Cancer Prevention by Liuwei Dihuangwan， Erzhiwan and Zuoguiwan Based on Macrophage Phagocytosis

Screening of Anti-breast Cancer Active Ingredients in Famous Classical Formula Yanghetang

Intervention of Breast Cancer by Regulating Wnt/β-catenin Signaling Pathway with Traditional Chinese Medicine： A Review

Role and Mechanism of Cucurbitacin B in Suppressing Proliferation of Breast Cancer 4T1 Cells via Inducing Ferroptosis

Characteristic Analysis of Effective Components and Compounds of TCM for Prevention and Treatment of Breast Cancer Based on Wnt/β-catenin Signaling Pathway Targeting

Related Author

ZHENG Lixiang

CHEN Yishan

QUAN Wei

ZHONG Youbao

GUO Zifeng

SU Sijia

ZHAO Xinyu

ZHOU Jingna

Related Institution

Jiangxi University of Chinese Medicine

Dongfang Hospital， Beijing University of Chinese Medicine

The First Affiliated Hospital of Heilongjiang University of TCM

The First Clinical Medical College of Heilongjiang University of Traditional Chinese Medicine （TCM）

School of Chinese Material Medica， Beijing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰